Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison? (Q34342944)

1 August 2017

Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison? (English)

1 reference

1 August 2017

1 reference

1

U Platzbecker

1 reference

1 August 2017

U Germing

2

1 reference

1 August 2017

6 May 2013

1 reference

1 August 2017

1 reference

1 August 2017

27

1 reference

1 August 2017

9

1 reference

1 August 2017

1813-1819

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2013.140

1 August 2017

0 references

cites work

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Aberrant methylation of the M-type phospholipase A(2) receptor gene in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Treatment of acute myelogenous leukemia with outpatient azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Advances in the 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Persistent malignant stem cells in del(5q) myelodysplasia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Unraveling the molecular pathophysiology of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

Impact of lenalidomide on the functional properties of human mesenchymal stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

Treatment of deletion 5q acute myeloid leukemia with lenalidomide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

Lenalidomide in AML: del(5q) or who?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.140

7 January 2021

Identifiers

DOI

10.1038/LEU.2013.140

1 reference

PubMed ID

23644421

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

23644421